COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,891 Articles (22,568 medRxiv, 8,323 bioRxiv)

Most recent first Previous |  Page 961: Articles 9601-9610  | Next

Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants
Banerjee, A., Lew, J., Kroeker, A., Baid, K., Aftanas, P., Nirmalarajah, K., Maguire, F., Kozak, R., McDonald, R., Lang, A., Gerdts, V., Straus, S. E., Gilbert, L., Li, A. X., Mozafarihasjin, M., Walmsley, S., Gingras, A.-C., Wrana, J. L., Mazzulli, T., Colwill, K., McGeer, A. J., Mubareka, S., Falzarano, D.
10.1101/2022.01.13.475409 — Posted: 2022-01-13
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Suryadevara, N., Shiakolas, A., VanBlargan, L., Binshtein, E., Chen, R., Case, J. B., Kramer, K., Armstrong, E., Myers, L., Trivette, A., Gainza, C., Nargi, R., Selverian, C., Davidson, E., Doranz, B., Diaz, S., Handal, L., Carnahan, R. H., Diamond, M. S., Georgiev, I., Crowe, J. E.
10.1101/2022.01.12.476120 — Posted: 2022-01-13
Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study
Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., Zinzani, P. L., Mantegazza, R., Tagliavini, F., Lupo Stanghellini, M. T., Ciceri, F., Damian, S., Uccelli, A., Fenoglio, D., Silvestris, N., Baldanti, F., Piaggio, G., Ciliberto, G., Morrone, A., Locatelli, F., Sinno, V., Rescigno, M., Costantini, M., VAX4FRAIL Study Group
10.1101/2022.01.12.22269133 — Posted: 2022-01-13
An ensemble prediction model for COVID-19 mortality risk
Li, J., Li, X., Hutchinson, J., Asad, M., Wang, Y., Wang, E.
10.1101/2022.01.10.22268985 — Posted: 2022-01-13
Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults
Kared, H., Wolf, A.-S. F. M., Alirezaylavasani, A., Ravussin, A., Solum, G., Tran, T. T., Lund-Johansen, F., Vaage, J. T., Nissen-Meyer, L. S., Nygaard, U. C., Hungnes, O., Robertson, A. H., Meyer Naess, L., Trogstad, L., Magnus, P., Munthe, L. A., Mjaaland, S.
10.1101/2022.01.13.22269213 — Posted: 2022-01-13
Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants
Chen, Z., Zhang, P., Matsuoka, Y., Tsybovsky, Y., West, K., Santos, C., Boyd, L. F., Nguyen, H., Pomerenke, A., Stephens, T., Olia, A. S., De Giorgi, V., Holbrook, M. R., Gross, R., Postnikova, E., Garza, N. L., Johnson, R. F., Margulies, D. H., Kwong, P. D., Alter, H. J., Buchholz, U. J., Lusso, P., Farci, P.
10.1101/2022.01.12.22269023 — Posted: 2022-01-13
matOptimize: A parallel tree optimization method enables online phylogenetics for SARS-CoV-2
Ye, C., Thornlow, B., Hinrichs, A. S., Torvi, D., Lanfear, R., Corbett-Detig, R., Turakhia, Y.
10.1101/2022.01.12.475688 — Posted: 2022-01-13
COVID-19 infection and vaccination rates in healthcare workers in British Columbia, Canada: A Longitudinal Urban versus Rural Analysis of the Impact of the Vaccine Mandate
Yassi, A., Barker, S., Lockhart, K., Taylor, D., Harris, D., Hundal, H., Grant, J. M., Okpani, A. I., Pollock, S., Sprague, S., Kim Sing, C.
10.1101/2022.01.13.22269078 — Posted: 2022-01-13
COVID-19 vaccine booster induces a strong CD8+ T cell response against Omicron variant epitopes in HLA-A*02:01+ individuals
Nguyen, A. T., Szeto, C., Chatzileontiadou, D. S. M., Tong, Z. W. M., Dewar-Oldis, M. J., Cooper, L., Murdolo, L. D., Chew, K. Y., Lineburg, K. E., Riboldi-Tunicliffe, A., Williamson, R., Gardiner, B. J., Jayasinghe, D., Lobos, C. A., Ahn, Y. M., Grant, E. J., Smith, C., McMahon, J., Good-Jacobson, K. L., Barnard, P. J., Short, K. R., Gras, S.
10.1101/2022.01.12.473243 — Posted: 2022-01-13
Estimation of age-stratified contact rates during the COVID-19 pandemic using a novel inference algorithm
Pooley, C. M., Doeschl-Wilson, A. B., Marion, G.
10.1101/2022.01.12.22269157 — Posted: 2022-01-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).